Media Conference

The Latest Media Conference

Information Meeting on GAZYVA®

Date:

November 07, 2018

Presentations:

1. Product Overview of GAZYVA® Intravenous Infusion 1000 mg
Naoko Oya, GAZYVA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab
Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan

2018

  • October 24, 2018
    3Q Results (Jan - Sep 2018) Conference Call
    FY2018 3Q Consolidated Financial Overview (IFRS based)
    Toshiaki Itagaki,
    Executive Vice President & CFO
    Overview of Development Pipeline
    Dr. Minoru Hirose,
    Department Manager of R&D Portfolio Management Dept.,
    Project & Lifecycle Management Unit
  • July 26, 2018
    Media Conference on FY2018 2Q Financial Results
    Aiming to Achieve Mid-term Business Plan “IBI 18”
    - FY2018 Half Year Results -
    Tatsuro Kosaka,
    President and CEO
    FY2018 2Q Consolidated Financial Overview (IFRS based)
    Toshiaki Itagaki,
    Executive Vice President and CFO
    Overview of Development Pipeline
    Dr. Yasushi Ito,
    Executive Vice President and Co-Head of Project & Lifecycle Management Unit
  • Jun 01, 2018
    Information Meeting on HEMLIBRA®
    1. HEMLIBRA® Subcutaneous Injection Product Overview
    Hiroshi Motegi, HEMLIBRA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA®
    Prof. Midori Shima, M.D., Ph.D.
    Department of Pediatrics, Nara Medical University
  • Apr 12, 2018
    Information Meeting on TECENTRIQ®
    1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
    Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
    2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
    Hiroyoshi Nishikawa, M.D., Ph.D.
    Department of Immunology, Nagoya University Graduate School of Medicine
    Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center
    3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
    Yuichiro Ohe, M.D.
    Deputy Director, Chief,
    Division of Thoracic Oncology
    National Cancer Center Hospital, Japan
  • Feb 01, 2018
    Media Conference on 2017.12 Financial Results
    Aiming to Achieve Mid-Term Business Plan “IBI 18”
    -2017 Results and 2018 Outlook-
    Tatsuro Kosaka, President, COO
    FY2017 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito, Senior Vice President,
    Head of Project & Lifecycle Management Unit

2017

  • Oct 30, 2017
    CEO Meeting
    Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry
    Chairman and CEO Osamu Nagayama
  • Jul 27, 2017
    Media Conference on FY2017 2Q Financial Results
    FY2017 2Q Consolidated Financial Overview
    Yoshio Itaya,
    Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito,
    Senior Vice President, Head of Project & Lifecycle Management Unit
  • Feb 01, 2017
    Media Conference on 2016.12 Financial Results
    Mid-Term Business Plan “IBI 18”
    -2016 Results and 2017 Outlook-
    Tatsuro Kosaka, President, COO
    FY2016 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yasushi Ito, Senior Vice President,
    Head of Project & Lifecycle Management Unit
    Reorganization to Provide a New Solution
    Susumu Kato, Senior Vice President,
    General Manager of Marketing & Sales Div.

2016

  • Jul 21, 2016
    Media Conference on FY2016 2Q Financial Results
    FY2016 2Q Consolidated Financial Overview
    Yoshio Itaya,
    Executive Vice President CFO
    Overview of Development Pipeline
    Minoru Watanabe,
    Associate Vice President
    Deputy General Manager of Research Division
  • May 19, 2016
    Joint Press Conference by Osaka University and Chugai Pharmaceutical Co., Ltd.
    Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.
    Executive Vice President of Research and Risk Management, Osaka University
    Yasushi Yagi
    Outline of Comprehensive Collaboration with IFReC
    CHUGAI PHARMACEUTICAL CO., LTD.
    Executive Vice President
    Yutaka Tanaka
  • Apr 05, 2016
    Information Meeting on Bonviva®
    1. Product Overview of Bonviva® Tablet
    Takeshi Sakaguchi
    Bonviva® Product Manager
    Chugai Pharmaceutical Co., Ltd.
    2. Bonviva® Tablet: Clinical Utility and Our Expectation
    Hiroshi Hagino, M.D., Ph.D., Professor
    School of Health Science
    Tottori University Faculty of Medicine, Japan
  • Jan 28, 2016
    Media Conference on 2015.12 Financial Results
    New Mid-Term Business Plan "IBI 18"
    Tatsuro Kosaka, President, COO
    FY2015 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President

2015

  • Jul 23, 2015
    Media Conference on FY 2015.12 2Q Financial Results
    FY2015 2Q Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President
  • Apr 02, 2015
    Information Meeting on ZELBORAF®
    1. Overview of ZELBORAF®
    Takahiro Mizui
    ZELBORAF® Lifecycle Leader
    CHUGAI PHARMACEUTICAL CO., LTD.
    2. cobas® BRAF V600 Mutation Test
    Toru Ogawa
    Manager, Molecular Diagnostics
    Roche Diagnostics K.K.
    3. ZELBORAF® tablet Postmarketing safety measures
    Shin Yoshida
    Pharmacovigilance Department
    CHUGAI PHARMACEUTICAL CO., LTD.
    4.Overview of melanoma and clinical trials of vemurafenib
    Naoya Yamazaki, M.D., Ph.D.
    Chief, Dept. of Dermatologic Oncology
    National Cancer Center Hospital, Japan
  • Jan 28, 2015
    Media Conference on 2014.12 Financial Results
    Aiming to Become a Top Pharmaceutical Company
    Tatsuro Kosaka, President, COO
    FY2014 Consolidated Financial Overview
    Yoshio Itaya, Executive Vice President, CFO
    Overview of Development Pipeline
    Yutaka Tanaka, Executive Vice President,
    Head of Project & Lifecycle Management Unit
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top